AstraZeneca shares fell about 7% on Monday after a report that the British pharmaceutical group has been in talks to combine with Bristol Myers Squibb in a deal that could value the merged company at roughly $400 billion.
The two companies have discussed a potential tie-up over several months, the Financial Times reported on Sunday, in what would rank among the largest transactions the pharmaceutical industry has ever seen. Neither company has publicly confirmed the negotiations.
The market reaction split sharply along the two sides of the reported deal. While AstraZeneca slumped, Bristol Myers Squibb shares climbed, a divergence that typically signals investor skepticism about the terms or strategic logic facing the acquiring party.
Analysts were quick to question the rationale for a merger of two firms with limited overlap in their core franchises. AstraZeneca has built momentum in oncology and rare diseases, while Bristol Myers Squibb has leaned on established blockbusters and immunology treatments, prompting doubts over where the combined entity would find meaningful synergies.
“The strategic fit is not obvious, and a deal of this scale would carry substantial integration and regulatory risk,” one industry analyst noted, capturing the puzzlement that rippled through equity desks as the reports circulated.
A combination on this scale would face intense antitrust scrutiny across the United States, Europe and other major markets, and could take well over a year to clear regulatory review even if both boards agreed to proceed.
The reported discussions come as large drugmakers weigh consolidation to offset looming patent expirations and to fund costly research pipelines. Bristol Myers Squibb has recently pointed to solid quarterly performance and raised its earnings outlook, while AstraZeneca has pursued a broad expansion strategy spanning cancer therapies and next-generation treatments, as detailed in earlier coverage of its push into radiopharmaceuticals for cancer care.
A merger of the two would create a company with a sprawling portfolio across oncology, cardiovascular disease, immunology and rare conditions, reshaping the competitive landscape for global pharmaceutical developers.
For now, the reports remain unconfirmed, and both companies have declined to comment on the market speculation. Investors will be watching closely for any formal statement or regulatory disclosure that could clarify whether the talks advance toward a binding agreement.